AGM
IRD

Alpine Global Management’s Opus Genetics IRD Stock Holding History

Alpine Global Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-42
Closed -$22K – 237
2014
Q1 		$22K Buy
+42
New +$22.7K 0.02% 152

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Alpine Global Management's IRD Position: Q2 2014 in Review

Alpine Global Management sold out of Opus Genetics (IRD) in Q2 2014, closing a stake of 42 shares — an estimated $22K sold.

Alpine Global Management first reported a position in IRD in Q1 2014 and held it in 1 quarter. The position peaked at $22K in Q1 2014. 35 funds tracked by Wall St. Rank hold IRD as of Q2 2014.

  • Alpine Global Management reported no remaining Opus Genetics position as of Q2 2014 after selling out during the quarter.
  • Alpine Global Management sold 42 Opus Genetics shares in Q2 2014, an estimated $22K.
  • Alpine Global Management first reported a position in Opus Genetics in Q1 2014 and held it in 1 quarter.
  • Alpine Global Management's Opus Genetics position peaked at $22K in Q1 2014.
  • 35 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2014.

Based on Alpine Global Management's 13F filing for Q2 2014, filed 14 Aug 2014.